Periorbital edema associated with alpelisib
Document Type
Article
Publication Date
6-22-2022
Publication Title
Cancer Treatment and Research Communications
Abstract
Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastrointestinal upset are the most commonly reported adverse events associated with alpelisib. Although rash is a known on-target effect of alpelisib, patients typically present with a morbilliform rash. We describe two cases of periorbital edema associated with alpelisib. We discuss the clinical findings, management, and prognosis of this unique reaction. These cases highlight the importance of early involvement of dermatology to manage adverse cutaneous events associated with alpelisib.
PubMed ID
35834907
Volume
32
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Recommended Citation
Dao, Elizabeth A.; George, Saira J.; Heberton, Meghan M.; Pacha, Omar; Kovitz, Craig A.; Patel, Anisha B.; and Phillips, Rhea M., "Periorbital edema associated with alpelisib" (2022). School of Medicine Faculty Publications. 4634.
https://digitalscholar.lsuhsc.edu/som_facpubs/4634
10.1016/j.ctarc.2022.100596
Comments
Erratum to article includes Declaration of Patient Consent statement that was not included in the published version of the article. It verifies that patient consent was obtained by the authors. See https://doi.org/10.1016/j.ctarc.2022.100654